NCT03091673 - Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 27, 2017

Primary Completion Date

September 7, 2017

Study Completion Date

September 27, 2017

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG

Glucagon

0.5 or 1.0 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector

Trial Locations (7)

Women & Children's Hospital of Buffalo, Buffalo

University of Florida, Gainesville

Indiana University, Indianapolis

University of Iowa, Iowa City

Barbara Davis Center for Childhood Diabetes, Aurora

Stanford University, Stanford

Yale University, New Haven